Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset.
While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to specific therapeutic regimens. This supplementary data is supportive to the research article entitled "Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer" [1]. Using electronic health records data from a large demographically and geographically diverse oncology database, we present real-world progression-free survival (rwPFS) outcomes for patients with advanced non-small cell lung cancer in the United States treated with either first-line immunotherapy as monotherapy or single-agent immunotherapy combined with chemotherapy. rwPFS was estimated for patients in each treatment group using Kaplan-Meier methods; analyses were conducted separately for patients with squamous and non-squamous histology and stratified by Eastern Cooperative Oncology Group performance status, tumor programmed death ligand-1 expression, and presence of brain metastases.
['Waterhouse|David|D|', 'Lam|Jenny|J|', 'Betts|Keith A|KA|', 'Yin|Lei|L|', 'Gao|Sophie|S|', 'Yuan|Yong|Y|', 'Hartman|John|J|', 'Rao|Sumati|S|', 'Lubinga|Solomon|S|', 'Stenehjem|David|D|']
Non-small cell lung cancer Real-world outcomes Immunotherapy Immune checkpoint inhibitors